Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lung Neoplasms 2Glioma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Ependymoma 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 47Rituximab 31fludarabine 29Specimen Handling 13Magnetic Resonance Spectroscopy 13Doxorubicin 13pirtobrutinib 11Vincristine 11Prednisone 11fludarabine phosphate 10Immunotherapy, Adoptive 10Etoposide 10Bendamustine Hydrochloride 10obinutuzumab 8Lenalidomide 8Biopsy 8venetoclax 7polatuzumab vedotin 7glofitamab 7zanubrutinib 6pembrolizumab 6Dexamethasone 6tafasitamab 5ibrutinib 5etoposide phosphate 5acalabrutinib 5Leukapheresis 5tazemetostat 4loncastuximab tesirine 4Nivolumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Pharmacogenomic Variants × 1 year × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡